4:09 PM
 | 
Feb 13, 2018
 |  BC Extra  |  Clinical News

Merck halts Phase III trial of AD candidate

Merck & Co. Inc. (NYSE:MRK) stopped the Phase III APECS trial of verubecestat (MK-8931) to treat prodromal Alzheimer’s disease after an external DMC said it was unlikely the trial would establish a positive benefit-risk profile for the candidate. Merck spokesperson Ian McConnell told BioCentury the company plans to conduct a...

Read the full 229 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >